MRK MRK メルク

Drugmaker Merck& Co. filed a lawsuit Tuesday alleging President Biden''s marquee effort to negotiate down the cost of drugs under Medicare is "tantamount to extortion" and violates the Constitution. Merck wants the court to block the Biden administration from enforcing the program, saying at least one of its drugs will be selected for the program and expose the… The post Merck sues to stop Biden''s drug-negotiation program appeared first on Insurance News | InsuranceNewsNet .

Merck (MRK) announced Thursday that the FDA accepted its marketing application seeking approval for Keytruda as a drug combo for a type of liver cancer. Read more here.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with standard of care chemotherapy (gemcitabine and cisplatin) for the treatment of patients with locally advanced

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer

The Latest Released Contraceptives market study has evaluated the future growth potential of Global Contraceptives market and provides information and useful stats on market structure and size. The report is intended to provide market intelligence and strategic insights to help

Abbvie (ABBV) and Bristol-Myers Squibb (BMY) competed to takeover Prometheus Biosciences (RXDX), before Merck (MRK) won in its pursuit of the biotech company. The interest from…

Merck & Co. edged out competitors including AbbVie Inc. and Bristol Myers Squibb Co. to prevail in its $10.8 billion takeover of biotechnology company Prometheus Biosciences Inc, according to people familiar with the matter.

LONDON, May 01, 2023 (GLOBE NEWSWIRE) -- The Business Research Company''s research on the targeted therapy market forecasts that the market is expected to expand from $97.3 billion in 2022 to $106.7 billion in 2023 , at a compound annual growth rate (CAGR) of more than 9 % . The targeted therapy market share is then projected to grow to $148.3 billion in 2027 at a CAGR of more than 8%. North America was the largest region in the market in 2022. The growing incidence of cancer is expected to drive the expansion of the targeted therapy market size in the coming years. According to the American Cancer Society''s 2021 report, 1.8 million new cases of cancer were diagnosed in 2020. The National Cancer Institute, a US government organization that is part of the National Institutes of Health, reported a 43% increase in new cancer cases registered in September 2020 compared to 2019. Learn More In-Depth On The Targeted Therapy Industry https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report Several prominent players operating in the targeted therapy market include Sanofi, Merck & Co., Inc., Pfizer Inc., …

The AUD is the strongest and the JPY is the weakest as new week, the new month and the North American session begins. The USD is mixed with the USD stronger vs the JPY, GBP, CAD, NZD and EUR and down vs the AUD and the CHF. Europe is mostly closed for May Day holiday. The AUDUSD moved above its 100 hour MA and swing lows from March 24 and April 10 were broken between 0.6618 and 0.6625, and that helped to push the pair higher. The next target goes between 0.6649 and 0.6852 (see green numbered circles in the chart below). Over the weekend, First Republic Bank has been taken over by Californian authorities, with JPMorgan Chase assuming its deposits, after more than $100 billion in deposits left the bank in Q1. It is the 3rd bank failure this year. This week, the big news will include the Fed meeting on Wednesday. The Federal Reserve is expected to increase interest rates by a quarter percentage point in its policy-setting meeting which some believer could be the last increase in its year-long tightening cycle.

The U.S. and EU regulators have agreed to review potential label expansion for anemia therapy Reblozyl developed by Bristol Myers (BMY) and Merck (MRK). Read more here.

NEW YORK CITY, New York: The Wall Street Journal has reported that Pfizer is in early-stage discussions regarding a potential multi-billion dollar deal to acquire cancer drugmaker Seagen. The move comes after advanced discussions in 2022 between Merck and Seagen fell through, due to concerns that the Federal Trade Commission would launch an antitrust investigation of both companies. The report said the of

Merck (MRK) and AstraZeneca (AZN) said Thursday that an FDA expert panel is set to discuss the company’s request to expand the label for cancer therapy Lynparza. Read the full story here.

AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) will convene a meeting of the Oncologic Drugs Advisory Committee (ODAC) to discuss the supplemental new drug application (sNDA) for use of LYNPARZA in combination with abiraterone and prednisone or prednisolone (abi/pred) for the treatment of

ResMed (US), Koninklijke Philips N.V. (Netherlands) and Fisher & Paykel Healthcare (New Zealand) are leading players in Sleep Apnea Devices Market Northbrook, IL 60062 -- ( SBWIRE ) -- 03/01/2023 -- The sleep apnea devices industry is expected to continue to experience growth in the near future. This is due in part to an aging population, increasing awareness of sleep apnea, and advancements in technology. In the near future, we can expect to see more innovative solutions to treat sleep apnea, such as wearable devices and connected technologies. We can also expect to see an increased focus on patient-centered care and greater access to sleep apnea treatments. Additionally, the sleep apnea devices industry is likely to benefit from an increase in government funding and research grants, as well as greater acceptance of alternative treatments. Sleep Apnea Devices market in terms of revenue was estimated to be worth $7.1 billion in 2021 and is poised to reach $9.9 billion by 2026, growing at a CAGR of 6.9% from 2021 to 2026 according to a latest report published by MarketsandMarkets™.

Merck (MRK) announced Wednesday its immunotherapy Keytruda reached one of the dual primary endpoints in a Phase 3 trial as perioperative therapy in lung cancer. Read the full story here.